Campbell, CA, United States
Campbell, CA, United States
SEARCH FILTERS
Time filter
Source Type

Tanaka S.,U.S. National Institutes of Health | Tanaka S.,National Institute of Neuroscience | Honda M.,National Institute of Neuroscience | Honda M.,SCI Solution | And 3 more authors.
Cerebral Cortex | Year: 2010

Behavioral studies have suggested that the stabilization of motor memory varies depending on the practice schedule. The neural substrates underlying this schedule-dependent difference in memory stabilization are not known. Here, we evaluated the effects of 1-Hz repetitive transcranial magnetic stimulation (rTMS) applied to different cortical regions and sham after one session of training (Day 1) of sequential motor skills acquired through blocked (each sequence was completely trained before training the next)-practice schedules and random (random training of 3 sequences)-practice schedules. The recall of sequences learned on Day 1 by Day 2 was measured in different groups of healthy volunteers. The rTMS over the supplementary motor area (SMA) but not over control regions or over the primary motor cortex (M1) immediately after practice or over SMA 6 h later reduced recall relative to sham only in the blocked-practice group. In contrast, recall in the random-practice group was unaffected by rTMS. These results document a differential contribution of the SMA to the stabilization of motor memories acquired through different practice schedules. More generally, they indicate that the anatomical substrates underlying motor-memory stabilization (or their temporal operation) do differ depending on the practice schedule. © The Author 2010. Published by Oxford University Press. All rights reserved.


Aoki Y.,Tokyo University of Agriculture and Technology | Aoki Y.,Kumiai Chemical Industry Co. | Matsumoto D.,SCI Solution | Kawaide H.,Tokyo University of Agriculture and Technology | Natsume M.,Tokyo University of Agriculture and Technology
Journal of Antibiotics | Year: 2011

Four germicidin homologs were isolated from a liquid culture of Streptomyces coelicolor A3(2). These were identified as germicidins A, B and C, and surugapyrone A (germicidin D). Absolute stereochemistry of the chiral center in germicidins A and C is determined to be S. All germicidins inhibited germination of S. coelicolor A3(2) spores above 1 g ml 1. S. coelicolor A3(2) spores collected from a single petri dish (9 cm i.d.) contained 5.4 g of germicidin A (2.7 × 10 14 g per spore), which accounts for 2.3% of the spore extract, and contents of germicidins B, C and D were 0.2-0.8 g. The activity of the spore extract corresponded well with the sum of the activity of each germicidin, which was estimated from the content and dose-response curve, which indicates that germicidins functions as self-germination inhibitors in S. coelicolor A3(2). Inhibitory action of germicidin A on spore germination was reversible and germicidin A inhibited not only spore germination but also hyphal elongation. © 2011 Japan Antibiotics Research Association All rights reserved.


Ovono D.N.,SCI Solution
Lecture Notes in Engineering and Computer Science | Year: 2016

A tricky way some courageous investors make money is precisely to buy or sell money itself! The exchange of foreign currency ("forex" market) is the purchase, or trade, of a particular currency from an individual or institution and the simultaneous sale of another currency at the equivalent value or current exchange rate. This exchange rate or price fluctuation is based on demand, political, social and economic events surrounding each country currency, this is a stochastic phenomenon, hence hard to predict, of course there is a strong potential for loss. Currencies are always traded in pairs. When someone says they are "buying the EUR/USD", they are buying Euros and selling Dollars. One challenge is to predict the rise and fall of the value so that one can make the decision to buy or sell a position. Another challenge is to select the best currency pair in term of return on investment. The innovative approach developed in this paper attempts to solve these challenges.


Okamoto T.,RIKEN | Okamoto T.,Gunma University | Endo S.,Tokyo Metropolitan University | Shirao T.,Gunma University | And 2 more authors.
Journal of Neuroscience | Year: 2011

We developed a new protocol that induces long-term adaptation of horizontal optokinetic response (HOKR) eye movement by hours of spaced training and examined the role of protein synthesis in the cerebellar cortex in the formation of memory of adaptation. Mice were trained to view 800 cycles of screen oscillation either by 1 h of massed training or by 2.5 h to 8 d of training with 0.5 h to 1 d space intervals. The HOKR gains increased similarly by 20-30% at the end of training; however, the gains increased by 1 h of massed training recovered within 24 h, whereas the gains increased by spaced training were sustained over 24 h. Bilateral floccular lidocaine microinfusions immediately after the end of training recovered the gains increased by 1 h of massed training but did not affect thegains increasedby 4 h of spaced training, suggesting that the memory trace of adaptation was transferred from the flocculus to the vestibular nuclei within 4 h of spaced training. Blockadeof floccular protein synthesis, examinedbybilateral floccular microinfusionsofanisomycin oractinomycin D1-4h before the training, impaired the gains increased by 4 h of spaced training but did not affect the gains increasedby 1 h of massed training. These findings suggest that the transfer of the memory trace of adaptation occurs within 4 h of spaced training, and proteins synthesized in the flocculus during training period may play an important role in memory transfer. © 2011 the authors.


Vinogradov V.V.,SCI Solution | Agafonov A.V.,SCI Solution | Vinogradov A.V.,Ivanovo State University of Chemistry and Technology
Journal of Sol-Gel Science and Technology | Year: 2010

Superhydrophobic films were obtained on the basis of sol-gel-derived titania or alumina/dodecylamine hybrid materials. It has been shown that wettability of surfaces of the inorganic oxides changes from superhydrophilic to superhydrophobic. For superhydrophobic materials, the surface roughness of the hybrid films on the basis of titania and alumina is 39 and 55 μm, respectively, and water contact angle is about 150°. © Springer Science+Business Media, LLC 2009.


Trademark
SCI Solution | Date: 2012-12-11

Golf shirts; Hats; Sweat pants; Sweat shirts; T-shirts.


Trademark
SCI Solution | Date: 2013-11-19

Beers; Mineral and Aerated Waters; Non-alcoholic Drinks, Namely, Carbonated Beverages, Beverages Containing Fruit Juices, Non-alcoholic Cocktail Mixes, and Fruit Juice Beverages; Fruit Drinks and Fruit Juices; Syrups and Syrup Substitutes for Making Beverages; Non-alcoholic Essences not in the Nature of Essential Oils for Making Beverages; Preparations for Making Beverages, Namely, Carbonated Beverages, Non-carbonated Beverages, Beverages Containing Fruit Juices, Non-alcoholic Cocktail Mixes, and Non-alcoholic Fruit Juice Beverages; Concentrates and Powders for Making Beverages, Namely, Non-alcoholic Carbonated Beverages, Non-alcoholic Beverages Containing Fruit Juices, Non-alcoholic Cocktail Mixes, and Non-alcoholic Fruit Juice Beverages; Non-alcoholic Beverages Enriched with Vitamins and Amino Acids and Infused with Herbal Extracts not for Medical Use.


Trademark
SCI Solution | Date: 2015-07-20

Beers; mineral and other non-alcoholic drinks; energy drinks; sports drinks; fruit drinks; fruit juices; syrups and other preparations for making beverages; non-alcoholic fruit extracts; extracts for making beverages; waters (beverages); lemonades; non-alcoholic cocktails.


PAREXEL enhances its Regulatory Cloud; leverages EMC® Documentum® for Life Sciences software solution suite to offer an end-to-end regulatory solution LONDON, 13th April, 2016 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, and EMC Corporation (NYSE: EMC) today announced they have entered into an alliance to offer an end-to-end Regulatory Information Management (RIM) and Regulatory Content Management solution. By combining PAREXEL® LIQUENT InSight® Regulatory Information Management platform and EMC® Documentum® for Life Sciences software solution suite, PAREXEL now provides life sciences companies with a complete solution for a product’s entire regulatory lifespan. Life science companies can utilise the solution for strategy and planning, authoring, publishing, submitting, viewing, archiving, and lifecycle management for a product. The offering is available through PAREXEL’s Regulatory Cloud, a life sciences content and regulatory information management solution structured within a dedicated, private cloud environment. “A life sciences company must navigate the complex, global and region-specific regulatory landscape to maintain registration and compliance for a product,” said Paul Bidez, Ph.D., Vice President and Global Head of Regulatory Solutions, PAREXEL. “To help solve this challenge for our clients, PAREXEL and EMC brought together our respective industry-leading regulatory information management platform and industry-leading life sciences content management solution suite within PAREXEL’s Regulatory Cloud.” PAREXEL’s Regulatory Cloud utilizes identity-based security that ensures that only authorised users can gain access to the infrastructure and application resources they require. Applications can be configured or integrated to meet client-specific requirements. The EMC Documentum for Life Sciences software solution suite can eliminate companies’ data silos to transform how organisations access, manage and share information across nonclinical, clinical, quality and regulatory groups, ensuring a single, authoritative source for regulated content. The fully-integrated suite leverages industry standards and utilises easily configurable, intuitive, and personalised interfaces to maximise productivity and ensure easy access to information. This helps to bring high-quality and safer drugs to market faster, improving health and well-being, while lowering costs. “Industry pressures are prompting biopharmaceutical organisations to adopt new business models, enter new global markets, and expand alliances and partnerships. To achieve these goals, Life Sciences organisations are becoming more strategic in how they manage information,” said Rohit Ghai, President, Enterprise Content Division, EMC. “By partnering with PAREXEL, we’re enabling these organisations to digitally transform and deliver high-quality, safer drugs to market faster and at a lower cost, while meeting regulatory requirements.” Regulatory Cloud is offered by PAREXEL directly or through the Company's Perceptive® Partner Program. About LIQUENT InSight Since the market introduction of LIQUENT InSight in 2004, 16 of the top 20 pharmaceutical companies have selected the LIQUENT InSight platform as their authoritative source of regulatory information. PAREXEL’s RIM technologies can also be coupled with comprehensive professional services from PAREXEL, which provides a full complement of Regulatory Outsourcing Services to help companies meet the demands of today’s complex and changing regulatory environment. About EMC Documentum for Life Sciences software solution suite Over 75% of leading life sciences firms rely on EMC Documentum. Our tightly integrated solutions deliver standardized business processes that simplify access to content. The EMC Documentum for Life Sciences software solution suite delivers proactive, automated, business rules and enhancements across the suite while ensuring a simple, user experience to reduce risk, streamline processes and boost worker productivity. Organizations can create a single authoritative source for regulated content, seamlessly link and share content across departments (or divisions) and provide proactive notifications to document authors, owners and users when document changes take place or actions and tasks are required. The suite includes: EMC Documentum Electronic Trial Master File, EMC Documentum Research and Development, EMC Documentum Submission Store and View, and EMC Documentum Quality and Manufacturing. About EMC EMC Corporation is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset — information — in a more agile, trusted and cost-efficient way. Additional information about EMC can be found at http://www.emc.com/. EMC and Documentum are registered trademarks or trademarks of EMC Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 77 locations in 51 countries around the world and had approximately 18,200 employees in the second quarter. For more information about PAREXEL International, visit www.PAREXEL.com. PAREXEL is a registered trademark of PAREXEL International Corporation. All other trademarks are the property of their respective owners. This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

Loading SCI Solution collaborators
Loading SCI Solution collaborators